Nobilis Influenza H5N2


adjuvanted inactivated vaccine against avian influenza virus type A, subtype H5

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

If you need more information about how this product may be used, you should consult your national veterinary authority. If you want more information on the basis of the CVMP's recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 25/03/2021

Authorisation details

Product details
Nobilis Influenza H5N2
Agency product number
Active substance
inactivated whole avian influenza virus antigen of H5N2 subtype (strain A/duck/Potsdam/1402/86)
International non-proprietary name (INN) or common name
adjuvanted inactivated vaccine against avian influenza virus type A, subtype H5
Anatomical therapeutic chemical veterinary (ATCvet) codes
Accelerated assessmentAccelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Publication details
Marketing-authorisation holder
Intervet International BV
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

18/03/2021 Nobilis Influenza H5N2 - EMEA/V/C/000118 - IG/1348

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for aves

Therapeutic indication

For active immunisation of chickens against avian influenza type A, subtype H5.

Efficacy has been evaluated on the basis of preliminary results in chickens. Reduction of clinical signs, mortality and excretion of virus after challenge were shown by three weeks after vaccination.

Serum antibodies could be expected to persist for at least 12 months after administration of two doses of vaccine.

Assessment history

How useful was this page?

Add your rating
2 ratings